Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration during general anesthesia or deep sedation. The affected drugs are liraglutide (Saxenda, Victoza), semaglutide (Ozempic, Rybelsus, Wegovy), and tirzepatide (Mounjaro, Zepbound).

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight loss. Whether you have type 2 diabetes or obesity, you may have heard about medications like Ozempic® that can help manage blood sugar levels and weight.

The FDA has added a new warning to drugs including Ozempic and Wegovy, cautioning that patients taking the drugs may be at a higher risk of inhaling gastric contents into their lungs while under

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under anesthesia.

"I'm using [Ozempic] off-label for a whole host of conditions — and have been for years," Dr. Caroline Messer, an endocrinologist at Northwell Lenox Hill Hospital, told The Post.

Dr. Danish Ali discusses the dangers associated with alternate versions of a popular weight loss drug. Deion Sanders imposed harsh punishment on Colorado players after they disregarded his game plan A Man Went on a Hike—and Found a Mysterious Cart Buried Under Ice for Decades US Navy destroyers unscathed after fighting off a complex attack of cruise and ballistic missiles and exploding drones How ‘Yellowstone’ Honored a Cowboy Legend Trump taps Elon Musk and Vivek Ramaswamy to lead Department of Government Efficiency The Brands Behind 19 Popular Kirkland Products At Costco The unhealthiest fast-food sandwich in America isn't a Big Mac,